ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticalsits history only182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industries140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatrisits history only130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose USits history only101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharmaits history only60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Teva Pharmaceutical Industries only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 22, 2011First study: phase 2 study in AsthmaFirst studyNCT01479621 · 909 enrolled · United States, Bulgaria, Croatia and more
  2. Apr 10, 2012Phase 2 study in AsthmaNCT01576718 · 889 enrolled · United States, Australia, Bulgaria and more
  3. Jan 17, 2013Phase 2 study in AsthmaNCT01772368 · 72 enrolled · United States
  4. May 9, 20142 phase 3 studies in AsthmaNCT02141854, NCT02139644
  5. Jun 24, 2014Phase 3 study in Persistent AsthmaNCT02175771 · 758 enrolled · United States
  6. Sep 18, 20142 phase 3 studies in Rhinitis, Allergic, SeasonalNCT02249663, NCT02246920
  7. May 5, 2015Phase 1 study in AsthmaNCT02437604 · 43 enrolled · United States
  8. Jul 1, 2015Phase 3 study in AsthmaNCT02496715
  9. Feb 9, 2016Phase 1 study in AsthmaNCT02680561 · 20 enrolled · United States
  10. Nov 30, 2016Phase 3 study in AsthmaNCT02980133 · 841 enrolled · United States, Georgia, Hungary and more
  11. Nov 27, 2018Phase 3 study in AsthmaNCT03756883 · 999 enrolled · United States
  12. Dec 11, 2020Phase 4 study in AsthmaNCT04677959 · 427 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 Teva Pharmaceutical Industries leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04677959Asthma · United States4CompletedMar 4, 2022427
NCT03756883Asthma · United States3CompletedOct 26, 2019999
NCT02980133Asthma · United States, Georgia, Hungary and more3CompletedApr 7, 2019841
NCT02680561Asthma · United States1CompletedJun 201620
NCT02496715Asthma3WithdrawnOct 20160
NCT02437604Asthma · United States1CompletedJul 201543
NCT02249663Rhinitis, Allergic, Seasonal · United States3UNKNOWNFeb 20151,535
NCT02246920Rhinitis, Allergic, Seasonal · United States3TerminatedJul 14, 20141,474
NCT02175771Persistent Asthma · United States3CompletedJul 2015758
NCT02141854Asthma · United States, Canada, Czechia and more3CompletedSep 2015882
NCT02139644Asthma · United States, Canada, Czechia and more3CompletedSep 2015787
NCT01772368Asthma · United States2CompletedJun 201372
NCT01576718Asthma · United States, Australia, Bulgaria and more2CompletedJul 2013889
NCT01479621Asthma · United States, Bulgaria, Croatia and more2CompletedJul 2013909

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.